Claims

1. Use of a Vasoactive Intestinal Peptide (VIP) in the manufacture of a medicament for the treatment of drug-induced pneumonitis.

2. The use according to claim 1, wherein the drug-induced pneumonitis is a checkpoint inhibitor-induced pneumonitis.

3. The use according to claim 1, wherein the drug-induced pneumonitis is a methotrexate-induced pneumonitis.

4. The use according to any of claims 1 to 3, wherein the VIP is provided in a pharmaceutical composition applicable for inhalation.

5. The use according to claim 4, wherein the pharmaceutical composition is provided in a liquid form.

6. The use according to claim 5, wherein the concentration of Vasoactive Intestinal Peptide in the pharmaceutical composition is from 20 mg/ml to 200 mg/ml, preferably from 35 mg/ml to 140 mg/ml, particularly preferred from 60 mg/ml to 80 mg/ml.

7. The use according to claim 4, wherein the pharmaceutical composition is provided in a solid form.

8. The use according to claim 7, wherein the concentration of Vasoactive Intestinal Peptide in the pharmaceutical composition is from 20 mg/mg to 200 mg/mg, preferably from 35 mg/mg to 140 mg/mg, particularly preferred from 60 mg/mg to 80 mg/mg.

9. The use according to any of claims 1 to 8, wherein the VIP is to be administered at a daily dose which ranges from 140 mg to 560 mg Vasoactive Intestinal Peptide.

10. The use according to any of claims 1 to 3, wherein Vasoactive Intestinal Peptide is to be administered to the patient as an aerosolized pharmaceutical composition by inhalation.

11. The use according to claim 10, wherein a liquid pharmaceutical composition is aerosolized for administration.

12. The use according to claim 11, wherein the concentration of Vasoactive Intestinal Peptide in the liquid pharmaceutical composition is from 20 mg/ml to 200 mg/ml, preferably from 35 mg/ml to 140 mg/ml, particularly preferred from 60 mg/ml to 80 mg/ml.

13. The use according to claim 10, wherein a solid pharmaceutical composition is aerosolized for administration.

14. The use according to claim 13, wherein the concentration of Vasoactive Intestinal Peptide in the solid pharmaceutical composition is from 20 mg/mg to 200 mg/mg, preferably from 35 mg/mg to 140 mg/mg, particularly preferred from 60 mg/mg to 80 mg/mg.

15. The use according to any of claims 1 to 3 or 10 to 14, wherein a daily dose from 140 mg to 560 mg Vasoactive Intestinal Peptide is to be administered.